ARK Next Generation Internet ETF vs Regeneron Pharmaceuticals Inc — how do they compare? ARK Next Generation Internet ETF trades at $148.16, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while ARK Next Generation Internet ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $812.27 |
52-Week Low | $114.45 | $555.51 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $147.92, up 3.11% today, with bullish technical signals from moving averages and a neutral oscillator stance. The ETF focuses on next-generation internet companies including AI and cloud infrastructure plays. Recent analysis highlights near-term headwinds from elevated capital spending but maintains long-term growth potential in agentic AI and physical AI technologies.
The ETF faces market skepticism around current AI infrastructure investments but offers exposure to innovative technology leaders. Key risks include sector concentration and volatility, while institutional interest remains strong in transformative technology themes driving long-term growth prospects.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →